We read with great interest the SPARE trial published in The Lancet Gastroenterology & Hepatology. 1 The authors are to be congratulated on this trial, as it provides important information guiding treatment de-escalation strategies for patients receiving combination immunosuppression for Crohn’s disease. The study assesses the outcome of infliximab retreatment, which is an important issue in routine clinical practice. 25 (35%) of 71 patients in the infliximab withdrawal group relapsed and were retreated with infliximab, and remission was achieved in 22 (96%) of 23 patients in that group. No infusion reactions or increased frequency of adverse events were associated with infliximab retreatment.
Keep Reading
Add A Comment